This filing discloses that Rapid Micro Biosystems will be acquired by Merck KGaA in an all-cash transaction valued at $0.75 per share. The acquisition is expected to close in December 2026, pending a tender offer and other closing conditions, and will integrate Rapid Micro Biosystems into Merck KGaA's Life Science business.
Rapid Micro Biosystems (RMBS) is being acquired by Merck KGaA in an all-cash deal for $0.75 per share. This represents a significant corporate catalyst for RMBS, as it provides a clear exit strategy and a defined valuation for its shareholders. For Merck KGaA (MRK), this acquisition strengthens its Life Science business by integrating Rapid Micro Biosystems' technology. The long closing timeline (December 2026) introduces some risk related to market conditions or regulatory hurdles, but the all-cash nature provides certainty for RMBS shareholders. Traders should note the potential for arbitrage opportunities in RMBS shares leading up to the closing, while monitoring any news regarding the tender offer and customary closing conditions.